Researchers have identified a pattern of longer overall survival in patients with stage IV rectal SCC than among patients with stage IV colon SCC.

For patients with metastatic primary pNETs, resection is associated with improved survival outcomes but also linked to perioperative complications.

Younger patients with neuroendocrine tumors have worse symptom burden health-related quality of life than older patients, researchers report.

The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...

CAPTEM (capecitabine and temozolomide) provided a high rate of disease control in patients with typical and atypical lung ...

Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.

Adding immunotherapy to chemotherapy can improve survival in patients with metastatic, poorly differentiated GEP-NECs, data suggest.

(HealthDay News) — The U.S. Food and Drug Administration (FDA) announced that it will fast-track review of nine experimental drugs. The move is part of a Trump administration program aimed at ...

We recommend that CTC should be routinely assessed and measured at diagnosis as part of risk evaluation,” study researchers wrote.

New research suggests that, among patients with neuroendocrine tumors, primary tumor sites differ by race, and overall survival outcomes differ by tumor site and gender.

A phase 1/2 study showed durable remission, manageable safety in pts with R/R follicular lymphoma who received fixed-duration mosunetuzumab.in.

Researchers presented efficacy and ongoing safety data from MonumenTAL-1, a phase 1/2 study assessing talquetamab in patients with multiple myeloma.